These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33624331)

  • 1. Anticoagulation in sub-Saharan Africa: Are direct oral anticoagulants the answer? A review of lessons learnt from warfarin.
    Semakula JR; Kisa G; Mouton JP; Cohen K; Blockman M; Pirmohamed M; Sekaggya-Wiltshire C; Waitt C
    Br J Clin Pharmacol; 2021 Oct; 87(10):3699-3705. PubMed ID: 33624331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.
    Kattoor AJ; Pothineni NV; Goel A; Syed M; Syed S; Paydak H; Mehta JL
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):428-434. PubMed ID: 31035795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulants uptake and an oral anticoagulation paradox.
    Kennedy C; Ni Choitir C; Clarke S; Bennett K; Barry M
    Br J Clin Pharmacol; 2020 Feb; 86(2):392-397. PubMed ID: 31747462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct Oral Anticoagulant Use in Special Populations: Elderly, Obesity, and Renal Failure.
    White EM; Coons JC
    Curr Cardiol Rep; 2021 Mar; 23(4):27. PubMed ID: 33655373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population-Based Study.
    Yu AYX; Malo S; Svenson LW; Wilton SB; Hill MD
    J Am Heart Assoc; 2017 Oct; 6(11):. PubMed ID: 29080863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.
    López-López JA; Sterne JAC; Thom HHZ; Higgins JPT; Hingorani AD; Okoli GN; Davies PA; Bodalia PN; Bryden PA; Welton NJ; Hollingworth W; Caldwell DM; Savović J; Dias S; Salisbury C; Eaton D; Stephens-Boal A; Sofat R
    BMJ; 2017 Nov; 359():j5058. PubMed ID: 29183961
    [No Abstract]   [Full Text] [Related]  

  • 8. Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
    Alamneh EA; Chalmers L; Bereznicki LR
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):183-200. PubMed ID: 26862063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation.
    Law SWY; Lau WCY; Wong ICK; Lip GYH; Mok MT; Siu CW; Chan EW
    J Am Coll Cardiol; 2018 Jul; 72(3):271-282. PubMed ID: 30012320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral anticoagulants and atrial fibrillation: A South African perspective.
    Laäs DJ; Naidoo M
    S Afr Med J; 2018 Jul; 108(8):640-646. PubMed ID: 30182879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-analysis.
    Mhanna M; Beran A; Al-Abdouh A; Sajdeya O; Abdulsattar W; Srour O; Ayesh H; Alom M; Khuder SA; Hamouda D; Assaly R
    Am J Ther; 2021 Jun; 28(5):e531-e539. PubMed ID: 34491953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 13. Direct Oral Anticoagulants in Atrial Fibrillation Patients With Concomitant Hyperthyroidism.
    Chan YH; Wu LS; See LC; Liu JR; Chang SH; Chao TF; Yeh YH; Kuo CT; Lee HF; Lip GYH
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32009154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation in real-world practice: a population-based cohort study protocol.
    Holbrook A; Dormuth C; Morrow R; Lee A; Troyan S; Li G; Pullenyegum E
    BMJ Open; 2016 Nov; 6(11):e013263. PubMed ID: 27884850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation.
    Lang NN; Connelly DT
    J R Coll Physicians Edinb; 2013; 43(2):151-8. PubMed ID: 23734359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
    Oertel LB; Fogerty AE
    J Am Assoc Nurse Pract; 2017 Sep; 29(9):551-561. PubMed ID: 28805310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding Risk of Direct Oral Anticoagulants in Patients With Heart Failure And Atrial Fibrillation.
    Jackevicius CA; Lu L; Ghaznavi Z; Warner AL
    Circ Cardiovasc Qual Outcomes; 2021 Feb; 14(2):e007230. PubMed ID: 33541109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
    Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
    Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.